APLLTD 주식 개요 알레믹 파마슈티컬스는 인도 및 전 세계에서 의약품을 개발, 제조 및 판매하는 회사입니다. 자세한 내용
생각, 링크 및 회사 내러티브를 캡처하세요.
Alembic Pharmaceuticals Limited 경쟁사 가격 내역 및 성능
다음에 대한 주가 최고가, 최저가 및 변동 요약 Alembic Pharmaceuticals 과거 주가 현재 주가 ₹1,055.15 52주 최고치 ₹1,303.90 52주 최저치 ₹746.50 베타 0.71 1개월 변경 1.28% 3개월 변경 사항 -9.44% 1년 변경 사항 36.47% 3년 변화 37.35% 5년 변화 86.54% IPO 이후 변화 2,109.74%
최근 뉴스 및 업데이트
Alembic Pharmaceuticals Limited Announces USFDA Tentative Approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% Dec 05
Earnings Miss: Alembic Pharmaceuticals Limited Missed EPS By 5.6% And Analysts Are Revising Their Forecasts Nov 10
Second quarter 2025 earnings: EPS and revenues miss analyst expectations Nov 08
Alembic Pharmaceuticals Limited Announces Superannuation of Vipul Gandhi, Head - Business Development - Formulations Nov 07
Alembic Pharmaceuticals Limited Receives Final Approval from the US Food & Drug Administration for its Abbreviated New Drug Application Diltiazem Hydrochloride Extended-Release Capsules Oct 21
Alembic Pharmaceuticals Limited to Report Q2, 2025 Results on Nov 07, 2024 Oct 18 더 많은 업데이트 보기
Alembic Pharmaceuticals Limited Announces USFDA Tentative Approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% Dec 05
Earnings Miss: Alembic Pharmaceuticals Limited Missed EPS By 5.6% And Analysts Are Revising Their Forecasts Nov 10
Second quarter 2025 earnings: EPS and revenues miss analyst expectations Nov 08
Alembic Pharmaceuticals Limited Announces Superannuation of Vipul Gandhi, Head - Business Development - Formulations Nov 07
Alembic Pharmaceuticals Limited Receives Final Approval from the US Food & Drug Administration for its Abbreviated New Drug Application Diltiazem Hydrochloride Extended-Release Capsules Oct 21
Alembic Pharmaceuticals Limited to Report Q2, 2025 Results on Nov 07, 2024 Oct 18
Now 21% overvalued after recent price rise Oct 15
Alembic Pharmaceuticals Limited Announces USFDAFinal Approval for Lamotrigine Extended-Release Tablets Usp, 200 mg, 250 mg, and 300 mg Oct 06
Alembic Pharmaceuticals Limited's (NSE:APLLTD) Intrinsic Value Is Potentially 17% Below Its Share Price Sep 25
Alembic Pharmaceuticals Limited Appoints Mr. Sudhakar Pandiyan as Head - Technical Operations Sep 16
Investor sentiment improves as stock rises 17% Sep 10
Price target increased by 7.2% to ₹1,056 Sep 10
Now 25% overvalued after recent price rise Sep 09
Is Alembic Pharmaceuticals (NSE:APLLTD) Using Too Much Debt? Sep 03
Alembic Pharmaceuticals Limited Receives Final Approval from the US Food & Drug Administration for Its Abbreviated New Drug Application Betamethasone Valerate Foam, 0.12% Aug 24
Alembic Pharmaceuticals Limited Announces Resignation of Nilesh Shah as Head Legal Aug 22
Alembic Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now Aug 13
First quarter 2025 earnings: EPS and revenues miss analyst expectations Aug 09
Alembic Pharmaceuticals Limited to Report Q1, 2025 Results on Aug 08, 2024 Jul 25
Alembic Pharmaceuticals Receives USFDA Final Approval for Fluphenazine Hydrochloride Tablets USP, 1 Mg, 2.5 Mg, 5 Mg, and 10 Mg Jul 24
Market Participants Recognise Alembic Pharmaceuticals Limited's (NSE:APLLTD) Earnings Pushing Shares 25% Higher Jul 20
Alembic Pharmaceuticals Limited Announces USFDA Tentative Approval for Selexipag for Injection, 1,800 Mc/Vial Jul 12
Alembic Pharmaceuticals Announces Usfda Final Approval for Bromfenac Ophthalmic Solution, 0.07% Jul 09
Upcoming dividend of ₹11.00 per share Jul 08
Alembic Pharmaceuticals Limited Receives USFDATentative Approval for Ivosidenib Tablets 250 Mg Jul 04
Now 21% overvalued Jul 01
Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Jun 25
Dividend increased to ₹11.00 Jun 24
Alembic Pharmaceuticals Limited, Annual General Meeting, Jul 22, 2024 Jun 10
Alembic Pharmaceuticals Limited Announces Superannuation of Chandrahas Shetty as President-Human Resources (India Branded Business) Jun 08
Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Rather Sparingly Jun 03
Now 20% overvalued May 29
Does This Valuation Of Alembic Pharmaceuticals Limited (NSE:APLLTD) Imply Investors Are Overpaying? May 11
Full year 2024 earnings released: EPS: ₹31.33 (vs ₹17.40 in FY 2023) May 10 Alembic Pharmaceuticals Limited Receives Various US Food & Drug Administration (Tentative or Final) Product Approvals
Alembic Pharmaceuticals Limited to Report Q4, 2024 Results on May 09, 2024 Apr 20
Price target increased by 8.4% to ₹933 Apr 12
Consensus EPS estimates increase by 14% Feb 12
Results: Alembic Pharmaceuticals Limited Exceeded Expectations And The Consensus Has Updated Its Estimates Feb 08
Price target increased by 7.4% to ₹827 Feb 07
Third quarter 2024 earnings: Revenues in line with analyst expectations Feb 06
Subdued Growth No Barrier To Alembic Pharmaceuticals Limited (NSE:APLLTD) With Shares Advancing 25% Jan 21
Alembic Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 05, 2024 Jan 19
Investor sentiment improves as stock rises 17% Jan 15
Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment? Jan 05 Alembic Pharmaceuticals Receives Various Us Food & Drug Administration Product Approvals
Alembic Pharmaceuticals Limited Appoints Pradeep Chakravarty as Head - Global Quality Dec 04
Alembic Pharmaceuticals Limited Announces Management Changes Nov 29
Alembic Pharmaceuticals Limited Announces Management Changes Nov 28
Alembic Pharmaceuticals Limited to Report Q2, 2024 Results on Nov 07, 2023 Oct 17
Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Can Manage Its Debt Responsibly Sep 27
Alembic Pharmaceuticals Limited Announces Resignation of Jesal Shah as Head - Strategy Sep 02
Alembic Pharmaceuticals Limited Announces That Mr. Nilesh Wadhwa, Head - International Business & Strategy (Formulations Business Development Division), Is Designated as Senior Management Personnel Aug 22
Price target increased by 10% to ₹659 Aug 07
First quarter 2024 earnings released: EPS: ₹6.14 (vs ₹3.35 loss in 1Q 2023) Aug 05
Alembic Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 04, 2023 Jul 24
Upcoming dividend of ₹8.00 per share at 1.2% yield Jul 21
Full year 2023 earnings: EPS exceeds analyst expectations Jun 24
Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Quite Sensibly Jun 09
Alembic Pharmaceuticals Limited, Annual General Meeting, Aug 04, 2023 Jun 06
Full year 2023 earnings: EPS exceeds analyst expectations May 07 Alembic Pharmaceuticals Limited Approves the Appointment of Jai Diwanji as an Independent Director
A Look At The Fair Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD) Apr 13
Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment? Feb 22
Consensus EPS estimates fall by 19% Feb 10
Third quarter 2023 earnings released: EPS: ₹6.20 (vs ₹8.98 in 3Q 2022) Feb 04
Consensus EPS estimates fall by 11% Feb 03
Alembic Pharmaceuticals Limited Announces Company Secretary and Compliance Officer Changes Feb 02
Alembic Pharmaceuticals Receives USFDA Tentative Approval for Acalabrutinib Capsules, 100 Mg Jan 20
Alembic Pharmaceuticals Limited Receives Final Approval from the US Food & Drug Administration Jan 07
Alembic Pharmaceuticals Limited (NSE:APLLTD) Shares Could Be 21% Below Their Intrinsic Value Estimate Jan 04
Now 20% undervalued after recent price drop Dec 20
Alembic Pharmaceuticals Limited Receives USFDA Final Approval for DesonideCream, 0.05% Dec 11
Alembic Pharmaceuticals Receives USFDA Final Approval for Diclofenac Sodium Topical Solution USP, 2% w/w Dec 01
Alembic Pharmaceuticals Receives USFDA Final Approval for Nifedipine Extended-Release Tablets USP, 30 Mg, 60 Mg and 90 Mg Nov 21
Consensus forecasts updated Nov 18
Insufficient new directors Nov 16
Alembic Pharmaceuticals Limited Receives US FDA Final Approval for Cyclophosphamide Capsules, 25 Mg and 50 Mg Nov 15
Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 13
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Alembic Pharmaceuticals Limited's (NSE:APLLTD) CEO For Now Nov 05
Investor sentiment improved over the past week Nov 03
Alembic Pharmaceuticals Receives Usfda Final Approval for Mesalamine Extended-Release Capsules Usp, 0.375 G Nov 03
Alembic Pharmaceuticals Limited to Report Q2, 2023 Results on Nov 11, 2022 Nov 02
Alembic Pharmaceuticals Limited (Alembic) Receives Final Approval from the Us Food & Drug Administration Oct 29
Alembic Pharmaceuticals Limited Announces Successful Completion of USFDA Inspection at Alembic Pharmaceuticals' Bioequivalence Facility at Vadodara Oct 27
Alembic Pharmaceuticals Limited, Annual General Meeting, Nov 11, 2022 Sep 16
Alembic Pharmaceuticals Limited Receives; U.S. Food & Drug Administration Final Approval for Chlorthalidone Tablets USP, 25 Mg and 50 Mg Aug 29
Consensus EPS estimates fall by 28% Aug 11
Upcoming dividend of ₹10.00 per share Aug 10
Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Has A Meaningful Debt Burden Aug 10
Price target decreased to ₹734 Aug 07
First quarter 2023 earnings released: ₹3.35 loss per share (vs ₹8.37 profit in 1Q 2022) Aug 05
Alembic Pharmaceuticals Limited to Report Q1, 2023 Results on Aug 04, 2022 Jul 21
Estimating The Intrinsic Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD) Jul 20
Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Jun 22
Alembic Pharmaceuticals Receives US Food & Drug Administration Tentative Approval for Dasatinib Tablets, 20 Mg, 50 Mg, 70 Mg, 80 Mg, 100 Mg, and 140 Mg Jun 11 주주 수익률 APLLTD IN Pharmaceuticals IN 마켓 7D -0.6% 0.8% -4.2% 1Y 36.5% 39.7% 19.1%
전체 주주 수익률 보기
수익률 대 산업: APLLTD 지난 1년 동안 39.7 %를 반환한 Indian Pharmaceuticals 업계보다 저조한 성과를 냈습니다.
수익률 대 시장: APLLTD 지난 1년 동안 19.1 %를 반환한 Indian 시장을 초과했습니다.
가격 변동성 Is APLLTD's price volatile compared to industry and market? APLLTD volatility APLLTD Average Weekly Movement 4.7% Pharmaceuticals Industry Average Movement 6.0% Market Average Movement 6.2% 10% most volatile stocks in IN Market 9.0% 10% least volatile stocks in IN Market 4.1%
안정적인 주가: APLLTD 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.
시간에 따른 변동성: APLLTD 의 주간 변동성 ( 5% )은 지난 1년 동안 안정적인 모습을 보였습니다.
회사 소개 알레믹 파마슈티컬스는 인도 및 국제적으로 의약품을 개발, 제조 및 판매하는 회사입니다. 이 회사는 심장학, 산부인과, 위장병학, 안과, 피부과, 신장/비뇨기과, 정형외과, 항감염, 감기 및 기침, 수의학, 항당뇨 등 다양한 치료 분야의 브랜드 전문 의약품과 경구용 고형제, 종양학 경구용 고형제 및 주사제, 일반 주사제 및 안과 제품, 피부과 및 구강 현탁액의 제네릭 제제, 활성 의약품 성분을 공급합니다. 또한 제품을 수출하고 있습니다.
자세히 보기 Alembic Pharmaceuticals Limited 기본 사항 요약 Alembic Pharmaceuticals 의 수익과 매출은 시가총액과 어떻게 비교하나요? APLLTD 기본 통계 시가총액 ₹207.40b 수익(TTM ) ₹6.47b 수익(TTM ) ₹63.57b
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) APLLTD 손익 계산서(TTM ) 수익 ₹63.57b 수익 비용 ₹17.44b 총 이익 ₹46.13b 기타 비용 ₹39.66b 수익 ₹6.47b
주당 순이익(EPS) 32.90 총 마진 72.56% 순이익 마진 10.17% 부채/자본 비율 20.4%
APLLTD 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기 기업 분석 및 재무 데이터 현황 데이터 마지막 업데이트(UTC 시간) 기업 분석 2024/12/22 08:06 장 마감 주가 2024/12/20 00:00 수익 2024/09/30 연간 수익 2024/03/31
데이터 소스 기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.
패키지 데이터 기간 미국 소스 예시 * 회사 재무 10년 애널리스트 컨센서스 추정치 +3년 시장 가격 30년 소유권 10년 관리 10년 주요 개발 사항 10년
* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.
명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.
분석 모델 및 눈송이 이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.
Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.
산업 및 부문 메트릭 업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.
애널리스트 출처 Alembic Pharmaceuticals Limited 26 애널리스트 중 11 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.
분석가 교육기관 Sarabjit Nangra Angel Broking Private Limited null null Antique Stockbroking Ltd. Vijayaraghavan Swaminathan Avendus Spark
23 더 많은 분석가 보기 
